Transforming Patient Outcomes In Chronic Diseases
ProterixBio is developing disease management platforms to improve patient outcomes, starting with pulmonary diseases. As a key part of these programs, ProterixBio will provide actionable biological measurements in order to improve patient assessment and enhance treatment decisions, solving critical unmet needs.
Our initial focus is COPD (chronic obstructive pulmonary disease), a progressive disease which causes reduced air flow in the lungs, leading to significant morbidity and mortality. The ultimate goal is to reduce the frequency and severity of exacerbations, slow progression, lower morbidity and mortality, and lower the overall cost of the disease.
ProterixBio is working with world class advisors to ensure the development of clinically useful tests which have a clear and compelling effect on patient outcomes. Our proprietary ViBE platform and AMMP assays enable efficient test development through the precise and reproducible analysis of proteins in blood, sputum and other sample types.
Enhancing Treatment Decisions To Improve Outcomes